New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
09:51 EDTDVA, FMSRevised CMS ruling favorable for dialysis providers, says Wells Fargo
Wells Fargo said the Centers for Medicare & Medicaid Services eliminated the impact of the rebase in its revised rules from for its proposed accountable care demonstration project for dialysis providers, which is a positive for the providers. The firm keeps an Outperform rating on DaVita HealthCare (DVA) and a Market Perform rating on Fresenius Medical (FMS).
News For DVA;FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
07:07 EDTFMSEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 15, 2015
10:01 EDTDVADaVita sees taking $250M reserve for Vanier litigation
In a regulatory filing yesterday related to a bond offering, DaVita noted it has received subpoenas or other requests for documents from the federal government in connection with the Vainer private civil suit, the Swoben private civil suit, the 2011 U.S. Attorney Medicaid investigation, the 2015 U.S. Attorney Transportation Investigation and the JSA investigation. In each of the Vainer and Swoben private civil suits, a relator filed a complaint against the company in federal court under the qui tam provisions of the False Claims Act and pursued the claims independently after the government declined to intervene. With regard to the Vanier private civil suit, the parties are engaged in active litigation. The parties in that suit completed discovery in early 2014; however, in August 2014, the court granted relators’ motion for sanctions and reopened discovery on a limited basis. The court in Vainer is considering the plaintiffs’ request for further sanctions, which could result in a range of outcomes from no other sanctions to plaintiffs’ request to strike our answer. Certain of these sanctions could materially adversely impact the company's ability to defend the case, DaVita said. "While we cannot predict the ultimate outcome of this case, if the case is resolved in favor of the plaintiffs, its resolution could have a material adverse effect on our earnings and cash flows. We recently commenced settlement discussions with the plaintiffs in Vainer." The company said it expects to accrue an estimated loss contingency reserve of $250M related to this matter. "Negotiations are ongoing and we can make no assurances as to whether the Vainer suit will settle and, if it does settle, whether it will settle for an amount higher than the current reserve," DaVita added. With regard to the Swoben private civil suit, in July 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint, and in October 2013 the plaintiff filed an appeal of the dismissal, which is currently pending.
07:41 EDTFMSEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
12:13 EDTDVADaVita announces $725.94M repurchase program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use